SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders weigh risk-on sentiment against rising bond yields and anticipate potential outcomes from US-China trade discussions. The community is closely watching for any signs of a "deal," with some suggesting that any positive news, even minor, could trigger a rally. Bullish sentiment remains despite mixed earnings reports from major tech companies and uncertainty surrounding future rate cuts.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders digest news from the Trump-Xi meeting and await key earnings reports from major tech companies. Community chatter revolves around potential market reactions, with some anticipating a pullback and others expecting continued upward momentum. Sentiment appears mixed as participants analyze the implications of the meeting's outcome and upcoming financial results in the tech sector.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending, fueled by community enthusiasm and discussions around its potential. The community is rallying behind the coin, emphasizing a shared vision and active development, while also celebrating its association with the $WAGMI meme. Conversations also highlight the coin's presence on the Solana blockchain and its potential for future growth.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Despite strong revenue growth, Meta Platforms is trending due to concerns about increased spending on AI and infrastructure, as well as a one-time tax charge impacting earnings. The community is debating whether the dip represents a buying opportunity or signals deeper issues with the company's investment strategy. Discussions also involve comparing Meta's situation and valuation to other tech giants like Google and Microsoft.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as it approaches a new all-time high, with many anticipating a continued climb and eyeing the $200 mark. Bullish sentiment is fueled by the company's AI prospects, its partnership with NVIDIA, and speculation around a potential stock split. However, some community members express concerns about the company's high valuation and potential for a pullback.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential, particularly around new projects and meme coins built on the network. The launch of a Solana ETF is also generating excitement. Despite some volatility, there's a strong sense of optimism and community support driving conversation around the cryptocurrency.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors analyze the implications of its recent earnings report, particularly its significant AI spending and Azure cloud growth. Community discussions revolve around whether the company's investments will translate to long-term gains, with some expressing concerns about near-term guidance and profitability, while others see it as a buying opportunity for a tech leader.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending as investors react to concerns about slowing sales and rising costs highlighted in the upcoming earnings report, with some analysts lowering price targets. The community is debating whether the stock is oversold, the impact of economic pressures on consumer spending at Chipotle, and the effectiveness of the current CEO. Some traders are also discussing portion sizes and pricing relative to competitors such as CAVA.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss its recent $900 million convertible note offering and its implications for the company's AI and data center expansion plans. Community members are debating whether the offering represents a strong vote of confidence or potential dilution, with some highlighting the favorable terms and Google's backing as bullish signals. The broader context involves TeraWulf's shift towards high-performance computing and AI, positioning it within the competitive landscape of clean energy and data center operations.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors analyze its potential following strong Q3 earnings, with revenue exceeding expectations and AI advancements driving growth. The community is focused on the company's increased capital expenditures and the potential impact of AI on its search revenues, considering whether GOOGL can reach new price targets. Some analysts see significant upside, citing the strength of Google's ad and AI strategy relative to peers.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

<ul class="summary-bullets"><li>Verastem reported early trial data showing its experimental oral therapy targeting KRAS-driven cancers was well-tolerated, with no severe gastrointestinal side effects.</li><li>Four of five evaluable patients showed tumor reduction, prompting optimism around the drug’s potential for pancreatic and colorectal cancer treatment.</li><li>Retail traders on Stocktwits responded enthusiastically, calling the update an example of improved, patient-focused design and praising the drug’s tumor-reducing effects.</li></ul>Verastem Oncology shares drew heavy retail chatter on Thursday after the company reported encouraging early results from its Phase 1/2a trial of VS-7375, an investigational oral KRAS G12D inhibitor targeting hard-to-treat solid tumors such as pancreatic and colorectal cancers.<h2 class="st-heading-2">Early Safety Data And Tumor Response</h2>The company said the first two monotherapy dose levels of 400 mg and 600 mg once daily&nbsp;were cleared with no dose-limiting toxicities, and no nausea, vomiting, or diarrhea above Grade 1 was observed. Of the five patients evaluable for efficacy, four experienced tumor reduction and remain on treatment.“Preliminary safety and tolerability data suggest VS-7375 can be administered at efficacious doses while effectively managing gastrointestinal side effects,” said CEO Dan Paterson, adding that the company is seeing “anti-tumor activity among pre-treated patients with advanced pancreatic cancer and other solid tumors.”<h2 class="st-heading-2">Combination Study Now Enrolling</h2>With monotherapy dose escalation continuing to 900 mg, Verastem said it has begun enrolling patients in a combination cohort testing VS-7375&nbsp;with cetuximab in KRAS G12D-mutant solid tumors, including colorectal cancer.Verastem’s Chief Medical Officer John Hayslip said the company is encouraged by the drug’s tolerability and early signs of anti-tumor activity, adding that the ongoing combination trial with cetuximab addresses “a significant unmet need for treatments specifically targeting KRAS G12D-mutant cancers.”The company plans to report an interim safety and efficacy update in the first half of 2026 and expand the trial globally following dose optimization.<h2 class="st-heading-2">Background On The Candidate</h2>VS-7375 is the lead program from Verastem’s collaboration with GenFleet Therapeutics, which is running a parallel study in China under the name GFH375. GenFleet previously selected 600 mg once daily as the recommended Phase 2 dose, citing similar safety and response patterns.The KRAS G12D mutation accounts for 26% of all KRAS mutations and is most prevalent in pancreatic, colorectal, endometrial, and lung cancers, which&nbsp;have few or no targeted treatment options.<h2 class="st-heading-2">Stocktwits Bulls Cheer Early Trial Results</h2>On Stocktwits, retail sentiment for Verastem was ‘extremely bullish’ amid a 123% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:967/134;" src="https://news.stocktwits-cdn.com/vstm_ss_jpg_a440d5807e.webp" alt="vstm ss.jpg" width="967" height="134"><figcaption>VSTM sentiment and message volume as of October 23 | Source: Stocktwits</figcaption></figure>One user said they were encouraged by Verastem’s latest update, calling it an example of how small refinements in trial design and dosing can meaningfully improve patient experience and tolerability.<stembedurl>https://stocktwits.com/CrozrX/message/633534378</stembedurl>Another user expressed optimism about Verastem, noting that the drug appeared to reduce tumor size while causing limited side effects.<stembedurl>https://stocktwits.com/UWilDue0/message/633520498</stembedurl><a href="https://stocktwits.com/symbol/VSTM">Verastem’s stock</a> has risen 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects

Four of five evaluable patients showed tumor reduction, prompting optimism around the drug’s potential for pancreatic and colorectal cancer treatment.

Equity

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouraging preliminary data from...

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...

Best Momentum Stocks to Buy for Oct. 21

VSTM, AS and SOTK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 21, 2025.

New Strong Buy Stocks for Oct. 21: NEM, AS and More

NEM, RY, AS, VSTM and SOTK have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 21, 2025.

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

The mean of analysts' price targets for Verastem (VSTM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VSTM News

VSTMVerastem Inc